ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecast
ACAD analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.10 / 5 from 20 analysts
- Price target
- $30.53 average of analyst targets
- Upside to target
- +59.7% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $0.21
- 52-week range
- $18.62 – $30.57
ACAD analyst ratings
20 analystsNumber of analysts at each rating.
ACAD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ACAD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.18 | $0.11 | $0.29 | $0.42 | −56.7% | 14 |
| Current fiscal year (2026) | $0.59 | $0.50 | $0.70 | $0.83 | −28.3% | 14 |
| Next fiscal year (2027) | $0.92 | $0.22 | $1.87 | $0.59 | +54.7% | 13 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ACAD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $332.4M | $325.0M | $338.6M | +19.3% | 18 |
| Current fiscal year (2026) | $1.27B | $1.25B | $1.31B | +18.7% | 19 |
| Next fiscal year (2027) | $1.43B | $1.34B | $1.58B | +12.4% | 18 |
ACAD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ACAD revenue: reported and forecast
ACAD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.13 | $0.18 | $0.19 | $0.18 | $0.18 | +44.2% | 1 up · 1 down |
| Current fiscal year (2026) | $0.38 | $0.60 | $0.60 | $0.60 | $0.59 | +56.0% | 13 up · 0 down |
| Next fiscal year (2027) | $0.89 | $0.89 | $0.89 | $0.90 | $0.92 | +3.3% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ACAD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ACAD beat in 9 of 12.
What analysts expect from ACAD
20 analysts cover ACADIA Pharmaceuticals; their consensus rating is buy (4.10 on a 1–5 scale, where 5 is a strong buy). The average price target is $30.53, 59.7% above the latest close of $19.12. Analysts expect earnings of $0.59 per share for 2026, −28.3% from a year earlier. For 2027 the average estimate is $0.92 per share on revenue of $1.4 billion. ACADIA Pharmaceuticals beat the EPS estimate in 9 of the last 12 quarters.
Related: ACAD income statement, ACAD key metrics, ACAD chart. See the ACAD stock overview for the latest quote and news.
ACAD forecast FAQ
What is ACADIA Pharmaceuticals's price target?
The average analyst price target for ACADIA Pharmaceuticals is $30.53, 59.7% above the latest close of $19.12.
Is ACADIA Pharmaceuticals a buy, hold or sell?
Of 20 analysts covering ACADIA Pharmaceuticals, 10 rate it a strong buy, 4 a buy, 5 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is ACADIA Pharmaceuticals's EPS forecast?
Analysts forecast $0.59 per share for 2026 (range $0.50 to $0.70); for 2027 the estimate is $0.92.
What is ACADIA Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $1.3 billion, growth of 18.7%; for 2027 it is $1.4 billion.
When does ACADIA Pharmaceuticals report earnings?
ACADIA Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $0.21.
Does ACADIA Pharmaceuticals usually beat earnings estimates?
ACADIA Pharmaceuticals reported EPS at or above the analyst estimate in 9 of the last 12 quarters.